[1] Castellanos MR, Hayes RL, Maiman MA.Synthetic peptides induce a cytotoxic response against human papillomavirus type18. Gynecol Oncol, 2001, 82:77-83.
[2] Rudolf MP, Man S, Melief CJ, et al. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res, 2001, 7(3 Suppl):788s-795s.
[3] Ruesch MN, Stubenrauch F, Laimins LA.Activation of papillomavirus late gene transcription and genome amplification upon differentiation in semisolid medium is coincident with expression of involucrin and transglutaminase but not keratin-10. J Virol, 1998, 72:5016-5024.
[4] Frazer IH, Thomas R, Zhou J, et al. Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev, 1999,168:131-142.
[5] Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med,1998, 4:37-42.
[6] Ronco LV, Karpova AY, Vidal M, et al.Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev, 1998, 12:2061-2072.
[7] Doan T, Chambers M, Street M, et al.Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic Tlymphocyte epitopes. Virology, 1998, 244:352-364.
[8] Pumpens P, Razanskas R, Pushko P, et al.Evaluation of HBs, HBc, and frCP viruslike particles for expression of human papillomavirus 16 E7 oncoprotein epitopes.Intervirology, 2002, 45:24-32.
[9] Speidel K, Osen W, Faath S, et al. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol, 1997, 27:2391-2399.
[10] Schafer K, Muller M, Faath S, et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer, 1999, 81:881-888.
[11] Steller MA, Gurski K J, Morakami M, et al.Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res, 1998, 4:2103-2109.
[12] Ressing ME, de Jong JH, Brandt RM, et al. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol, 1999, 29:1292-1303.
[13] Muderspach L, Wilczynski S, Roman L, et al. A phase Ⅰ trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res, 2000, 6:3406-3416.
[14] Youde SJ, Dunbar PR, Evans EM, et al.Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.Cancer Res, 2000, 60:365-371.
[15] Bourgault Villada I, Beneton N, Bony C,et al. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur J Immunol, 2000, 30:2281-2289.
[16] van der Burg SH. Ressing ME, Kwappenberg KM, et al. Natural T-helper immunity against human papillomavirus type 16(HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class Ⅱ-restricted epitopes. Int J Cancer, 2001.91:612-618.
[17] Zwaveling S, Ferreira Mota SC. Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol, 2002, 169:350-358.
[18] Van Regenmortel MH, Muller S. D-peptides as immunogens and diagnostic reagents. Curr Opin Biotechnol, 1998, 9:377-382.
[19] Reynolds SR, Oratz R, Shapiro RL, et al.Stimulation of CD8 + T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.Int J Cancer, 1997, 72:972-976.
[20] Einstein MH, Cruz Y, El-Awady MK, et al.Utilization of the human genome sequence localizes human papillomavirus type 16 DNA integrated into the TNFAIP2 gene in a fatal cervical cancer from a 39-year-old woman. Clin Cancer Res, 2002,8:549-554.
[21] Silins I, Avall-Lundqvist E, Tadesse A, et al. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol,2002, 85:333-338.
[22] Nemeckova S, Stranska R, Subrtova J, et al. Immune response to E7 protein of human papillomavirus type 16 anchored on the cell surface. Cancer Immunol Immunother, 2002. 51:111-119. |
